07 January 2020 | News
For Development of YS-ON-001/002 and Tavo-301/303 Combination Therapy for Cancer Treatment
Image credit- shuttershock.com
China headquartered Yisheng Biopharma Co., Ltd., a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, and Tavotek Biotherapeutics, a China and US based biotech company focusing on novel multi-specific antibodies in immuno-oncology and autoimmune diseases, announced that the companies have entered into a strategic research alliance and collaborate in the development involving their lead assets in oncology.
The objective of the alliance is to co-develop a combination therapy of YS-ON-001/002 and Tavo-301/303 for cancer treatment. The two companies are also in discussions regarding additional research and development collaborations beyond oncology.
YS-ON-001 and YS-ON-002 are immunotherapeutic products based on the TLR3/RIG-I/MDA-5 signaling pathways of PIKA® immunomodulating technology. They are capable of both reducing the immunosuppressive effect of tumor microenvironment and enhancing the anti-tumor function of the immune system to tumor cells. YS-ON-001 is currently in clinical development in China and Singapore, and has received orphan drug designations from the U.S. FDA for treatment of pancreatic and liver cancers. The product has been approved in Cambodia for the treatment of advanced solid tumors. YS-ON-002 is a clinical candidate ready for IND submission. YS-ON-001/002 can be an integral immunotherapy component with standard of oncology care, such as chemotherapies, targeted therapies and checkpoint inhibitors or with emerging immunotherapies for additive or synergistic treatment benefits.
Tavo-301/303 is a series of novel multi-specific antibody-based Immuno-Oncology assets that was developed using Tavotek's proprietary TavoSelect™ Platform. Novel protein engineering employing TavoSelect™ technology generates multi-specific biologics with optimal molecular profiles for targeting multiple relevant epitopes simultaneously to manage difficult-to-treat solid tumors. These biologics modulate the immunosuppressive pathway by multiple mechanisms of action to promote anti-tumor response and efficacy. The TavoSelec™ technology also provides biologic molecules with favorable pharmacokinetic profiles and stable formats for ease of development and manufacturing.